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Several vasoactive substances are generated in
the kidney. One is kallikrein, an enzyme generated
in the renal cortex that catalyzes the formation of
the vasodilator hormone lysyibradykinin (kallidin)
from plasma alpha-2 globulin substrate, kininogen.
Urinary kallikrein and kinin appear to be derived
from the kidney and differ from those in circulating
plasma. In our previous study [1], the intrarenal
arterial infusion of synthetic bradykinin did not
cause any increase in kinin excretion in urine col-
lected directly from the ipsilateral ureter in dogs, in
spite of the occurrence of a prominent diuresis and
natriuresis. This suggests that circulating plasma
kinin filtered through the glomeruli might be rapidly
destroyed by kininase II in the proximal tubule and
that kinin excreted in the urine might originate from
the renal tubules. Nustad, studying the distribution
of kallikrein in the rat renal tissue, found almost all
the activity to be in the renal cortex, whereas he
found only a little activity in the medulla [211. A
similar result was obtained in the dog by Carretero
and Scicli [3]. Their study with the stop-flow meth-
od has shown that renal kallikrein is secreted into
the tubular lumen at the level of the distal tubule.
This observation is in agreement with the study [41
on the immunohistochemical localization of kalli-
krein in the same part of the renal tubule that is
juxtaposed to the enzyme renin, located in the wall
of the glomerular afferent arteriole. From these
results, it is reasonable to presume that a major site
of kinin generation is in the distal tubule and that
the generated kinin is secreted into the urine at this
site. Now, it is generally accepted that the urinary
excretion of kallikrein and kinin reflects the genera-
tion and/or the release of renal kallikrein and kinin
from the kidney.
The renal medulla and papilla are a rich source of
prostaglandin (PG) synthetase [51. Since the discov-
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ery and identification of PGE2, PGA2, and PGF2.
from the rabbit renal medulla by Lee et al [6], many
studies have been done. The observations that
PGE2 and PGA2 not only lowered blood pressure
but also had notable effects on enhancing renal
blood flow, diuresis, and natriuresis, and that
PGA2, unlike PGE2, was not degraded in its passage
across the pulmonary circulation [7] suggested that
PGA2 might be a circulating hormone. But, there is
no evidence that PGA2 is a normal enzymatic
product in the kidney. According to Larsson and
Anggard [8], PGA2 was not found in amounts
exceeding 10% of the PGE2 content in the rabbit
renal medulla, analyzed by gas chromatographic-
mass spectrometric determination. Thus, the major
PG's in the renal medulla are PGE2 and PGF2a.
PGE2 has a very short half-life in blood, because it
is removed almost completely by a single passage
through the pulmonary circulation. Therefore, it is
very difficult to evaluate the pathophysiologic roles
of renal PGE2 by estimating its concentration in
peripheral blood. Frölich et al [9] have shown,
however, that renomedullary PG's are excreted in
urine and that their excretion rates reflect the
synthesis or the release of renal PG's.
Previous animal experiments have shown that
there are complicated interactions between renal
kallikrein-kinin and renin-angiotensin-aldosterone
or renal kallikrein-kinin and renal PG's. The obser-
vations by ErdOs and Yang [10] that the kidney has
a very rich kininase content and that kininase II,
located in proximal tubule, is identical with the
angiotensin I converting enzyme linked the renal
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kallikrein-kinin system to the renin-angiotensin sys-
tem. There are several reports indicating another
linkage of these two systems. Geller et al [11]
showed that the urinary excretion of kallikrein was
increased after the administration of deoxycortico-
sterone acetate (DOCA) in rats, but that it was
decreased after bilateral adrenalectomy. Margolius,
Chao, and Kaizu 11121 also reported that the release
of kallikrein from a rat renal cortical cell suspension
was increased after the addition of aldosterone and
decreased after the addition of the aldosterone
antagonist, spironolactone, indicating that the gen-
eration or the release of renal kallikrein is regulated
by aldosterone or some other sodium-retaining ste-
roid hormones. Mills et al [131 found that the uri-
nary excretion of kallikrein was increased after the
intrarenal arterial infusion of angiotensin II (All) in
the dog, suggesting that All may directly contribute
to the regulation of renal kallikrein release. These
reports strongly support the existence of an interac-
tion between renal depressor substances (the kalli-
krein-kinin system) and adrenorenal pressor sub-
stances (the renin-angiotensin-aldosterone system).
On the other hand, McGiff, Itskovitz, and Ter-
ragno [141 reported that the intrarenal infusion of
bradykinin stimulates the release of a PGE-like
substance from the dog kidney, with an enhance-
ment of renal blood flow and water and sodium
excretion. This enhancement of the PG release and
the renal vasodilator action of kinin was prominent-
ly attenuated after the inhibition of endogenous PG
generation by indomethacin, suggesting that there is
a coupling between the kinin and the PG systems
within the kidney. Kinins increase PG synthesis,
and the P0, in turn, modifies the effects of kinin on
the renal hemodynamics and excretory function.
Recently, Nasjletti, McGiff, and Colina-Chourio
[151 reported that the administration of DOCA or
aldosterone increased the urinary excretion of kalli-
krein and POE and produced polyuria but did not
affect sodium excretion, suggesting that interac-
tions of mineralocorticoid hormones, kinins, and
PG' s may be important in the maintenance of salt-
water homeostasis.
There is also close interaction between the renal
PG's and the renin-angiotensin system. According
to the reports by McGiff et al [16], the intrarenal
arterial infusion of All stimulated the release of PG
from the kidney, counteracting the vasoconstricting
effect of All. On the other hand, Larsson, Weber,
and Anggard [171 reported that the enhanced PG
synthesis induced by the administration of the PG
precursor, arachidonic acid, raised the plasma renin
activity, whereas inhibition of PG synthesis with
indomethacin decreased plasma renin activity, sug-
gesting that the renal PG system may contribute to
the renin release mechanism.
Previous reports concerning the roles of renal
kallikrein-kinin and renal PG's in renal sodium
handling have been conflicting. The intrarenal infu-
sion of kallikrein-kinin and also of POE results in a
prominent natriuresis and diuresis, indicating that
renal kallikrein-kinin and renal POE may be in-
volved in the regulation of renal sodium excretion
[18, 19]. Marin-Grez, Cottone, and Carretero [20]
found that kinins in blood obtained from the inferior
vena cava and urinary kallikrein excretion were
increased after acute intragastric salt loading in the
dog, whereas blood kinins were not increased in
bilaterally nephrectomized, sodium-loaded dogs. In
contrast to sodium loading, kallikrein excretion was
less in the urine of water-loaded dogs than it was in
sodium-loaded dogs, and no change in the circulat-
ing kinins was observed in the dogs with water-
loading. Their results suggest that the increase of
plasma kinin after acute sodium loading depends on
the presence of the kidney and that the activated
kallikrein-kinin might be contributing to the mecha-
nism of sodium handling. Marin-Grez, Oza, and
Carretero [21] also reported that urinary kallikrein
was increased in dogs in a state of escape from the
sodium-retaining effect of DOCA. On the contrary,
there are many reports stating that urinary excre-
tion of kallikrein was decreased during a high
sodium diet and increased during a low sodium diet
in animals as well as in man [22—25].
Studying the roles of renal POE in renal sodium
handling, Tobian and O'Donnell [26] found that the
renal PGE content in the rat was decreased after
sodium loading, which suggests that renal POE may
act as an antinatriuretic hormone. In contrast, our
previous reports [25, 27] showed that there was a
significant positive correlation between urinary
POE excretion and urinary sodium excretion in
normal volunteers and in patients with essential
hypertension, suggesting that renal POE may con-
tribute to the renal sodium excretion. As shown
[25], there are complicated regulatory mechanisms
in the release of renal kallikrein and also complicat-
ed interactions among the renal vasoactive sub-
stances.
The present study was done to investigate the
physiologic regulatory mechanism of generation
and/or release of renal kallikrein and kinin in rela-
tion to the renin-angiotensin-aldosterone system
and renal PGE in man by measuring the urinary
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excretion of kallikrein, kinin, PGE2, and PGF2a,
plasma renin activity (PRA), and plasma aldoster-
one concentration (PAC) under physiologic condi-
tion. The renin-angiotensin-aldosterone system was
stimulated with a low sodium diet and furosemide
injection, and the system was suppressed with a
high sodium diet and the aldosterone antagonist
spironolactone. Endogenous PG generation was
suppressed by indomethacin. Acute plasma volume
expansion was produced with saline infusion or
water loading.
Methods
Urinary kinin. Urinary kinin was measured by the
method of Carretero et al [28] and Abe et al [29].
Collected urine was stored immediately at —20° C
until the assay. The radioimmunoassay was per-
formed in 0.1 M Tris hydrochloric acid buffer (pH,
7.4) containing 0.2% of gelatin and 0.1% of neomy-
cm (buffer A). The incubation system consisted of
'251-8-tyrosine-bradykinin, 3000 cpm (specific ra-
diologic activity, 800 to 1000 mCi4iM; Daiichi Ra-
dioisotope Corp.), urine (0.01 to 0.05 ml), and
antiserum (0.1 ml; 1:16,000), adjusted to a final
volume of 0.8 ml with buffer A. The mixture was
incubated for 24 hours at 4° C, and free kinin was
separated with dextran-coated charcoal. After the
radioactivity was counted, the kinin content was
calculated. This method is sensitive down to 10 pg
of kallidin. The recovery rate of added kallidin (50
to 500 pg) was 97 4% (mean SEM, N = 15). The
metabolic fragments produced by incubating brady-
kinin, kallidin, and methionyl-lysyl-bradykinin with
chymotrypsin showed a 0.5% crossreaction with
kinin antiserum. The values of urinary kinin deter-
mined by the present method in 32 subjects showed
a highly significant correlation with the values de-
termined by a bioassay consisting of extraction and
assay using the autoperfused dog femoral arterial
blood flow (r = 0.71, P < 0.001).
Urinary kallikrein. Urinary kallikrein activity was
measured as the kininogenase activity by the radio-
immunoas say of generated kinin [291. Urine (0.05 to
0.1 ml) was incubated with 4 pg of low-molecular-
weight kininogen (supplied by Dr. Kato, Protein
Research Institute, Osaka) dissolved in 0.4 ml of 0.1
M phosphate buffer (pH, 8.4) containing 0.1% neo-
mycin, 3 mt 8-hydroxyquinoline, and 30 mi diso-
dium ethylenediaminetetraacetic acid (EDTA) at
37° C for 20 mm. After the incubation, the mixture
was diluted with distilled water, heated at 80° C for
15 mm to stop the enzymatic reaction, and stored at
—20° C until the measurement. The kinin generated
during the incubation was determined radioimmun-
ologically. In the present method, the extraction
procedure was not necessary, because low-molecu-
lar-weight kininogen had no crossreaction to the
antiserum. The values of urinary kallikrein deter-
mined by the radioimmunoassay in 31 subjects
showed a highly significant correlation with the
values determined by the esterolytic activity of p-
tosyl-arginine-methyl-ester (TAME) (r = 0.78, P <
0.001).
Urinary prostaglandin. Urinary PGE was mea-
sured radioimmunologicaily [30]. PGE in urine (3 to
5 ml) was converted to PGB by alkaline treatment
according to Zusman's method [31]. Then, the
sample was acidified to a pH of 3 to 4 with hydro-
chloric acid and extracted with ethyl acetate. The
organic phase was dried, and the residue was ap-
plied to a silicic acid column; PGB was eluted by a
mixture of benzene-ethyl acetate (60:40) according
to the method of Jaffe, Behman, and Parker [32].
The PGB fraction was dried and measured radioim-
munologically using PGB antiserum (CA 501, Clini-
cal Assay), which does not distinguish PGB1 from
PGB2. The overall recovery rate of added PGB (1 to
3 ng) was 54.8 0.7% (mean SEM, N = 15). The
estimated value was corrected for this loss.
Urinary PGF2a also was measured radioimmuno-
logically. Urine (3 to 5 ml) was acidified to a pH of 3
to 4 with hydrochloric acid and extracted with ethyl
acetate. The organic phase was dried, the residue
was applied to a silicic acid column, and PGF2. was
eluted by mixture of benzene-ethylacetate-metha-
nol (60:40:20). The PGF2a fraction was dried and
measured radioimmunologically using PGF2c. anti-
serum.
The major urinary metabolite of PGF2a (5a, 7a-
dihydroxy- 1 1-keto tetranor pro Stan-i, 16-dioic acid)
was measured by the method of Ohki, Hanyu, and
Imaki [33]. Diluted urine (corresponding to 0.01 to
0.05 ml of original urine) was directly measured
radioimmunologically using PGF2-MUM antise-
rum and the PGF2a urinary metabolite '251-tyrosine
methyl ester amide. This antiserum did not cross-
react with the principal PGE1 urinary metabolites
15-keto PGF2a, 15-keto PGE1, and 15-keto PGE2.
Plasma renin activity. PRA was determined by
radioimmunoas say of angioten sin I (Al) [34]. Plas-
ma, 1.0 ml, was adjusted to a pH of 5.5 and
incubated at 37° C for 6 hours with EDTA and
diisopropyl fluorophosphate (DFP). After the incu-
bation, the sample was diluted tenfold with physio-
logic saline and heated in a boiling water bath for 15
mm. After centrifugation, Al in the supernatant was
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assayed radioimmunologically. PRA was expressed
in terms of nanograms of generated AT per milliliter
of plasma per hour of incubation. This method was
approximately four times more sensitive than the
method of Haber et al [35].
Plasma aldosterone concentration. PAC was
measured with a commercial radioimmunoassay kit
(Cer Ire Sorin). This method is sensitive down to 10
pg of aldosterone.
Electrolytes. Serum and urinary sodium and po-
tassium were measured with an autoanalyzer. All
results were expressed as the means SEM. The
significance of differences was evaluated by Stu-
dent's t test.
Ad lib sodium diet. Eighty-four healthy subjects
(61 men and 23 women; 40.0 1.6 years) were
allowed to be on an unrestricted sodium diet and
were hospitalized during the study. Blood was
sampled in the morning after an overnight fasting,
and 24-hr urine samples were collected in a bottle
kept in a refrigerator.
Circadian variation. Healthy male physicians,
aged 30 to 46 years, were included in this study.
They were allowed to take an unrestricted diet. The
subjects kept a supine position in a bed throughout
the study except during urination, defecation, and
meals. The study commenced at 9:00 A.M. All
subjects emptied their bladders at this time, and the
specimens were discarded. Urine was collected
every 3 hours, and venous blood was sampled every
6 hours.
Influence of low sodium diet and high sodium
diet. Advanced cases of hypertension, 5 men and 2
women, ranging in age from 23 to 51 years, hospital-
ized in our clinic with the diagnosis of essential
hypertension (6 cases) and renovascular hyperten-
sion (1 case), were studied. Antihypertensive medi-
cation was discontinued at least for 2 weeks. They
were given a diet containing 200 mEq of sodium
daily for a week and then 30 mEq of sodium for 5
days, 350 mEq of sodium for 5 days, 350 mEq of
sodium with 96 mEq of potassium for 3 days, and
finally 350 mEq of sodium with unrestricted potassi-
um diet for 3 days. Twenty-four hour urine samples
were collected during each period.
Influence of acute water loading. Eight hospital-
ized hypertensive patients (4 men and 4 women; 25
to 57 years), including 7 cases of essential hyperten-
sion and 1 case of renovascular hypertension, were
subjected to this study. They were given an unre-
stricted diet. After the collection of 24-hour urine
samples (U1), the patients were kept supine for 2
hours in the next morning, and urine was collected
during this period as a control (U2). Then, water (20
ml/kg) was ingested over 45 mm, and urine was
collected serially at the end of the loading (U3) and
every 30 mm thereafter for 2.5 hours (U4 to U8).
Blood samples were taken before and 75, 135, and
195 mm after the water loading.
Influence of acute saline infusion. Twenty hospi-
talized hypertensive patients (11 men and 9 women,
21 to 53 years) were studied. They were given an
unrestricted diet. After overnight fasting, the sub-
jects were kept in a supine position for 2 hours.
Urine and blood samples were obtained, and then
physiologic saline was infused i.v. at a constant rate
of 10 ml/min for 100 mm. After the infusion, urine
and blood samples were again collected.
Furosemide administration and upright posture.
Sixteen healthy volunteers (12 men and 4 women,
27.7 2.3 years) were included in this study. The
subjects were allowed to take an unrestricted diet.
After overnight fasting, the subjects were kept in a
supine position for at least 1 hour, and then furose-
mide (1 mg/kg) was injected into the antecubital
vein. The subjects remained in an upright posture
for 120 mm thereafter. Urine and blood samples
were obtained before and 30 and 120 mm after the
furosemide administration.
Administration of spironolactone. Three patients
with essential hypertension were allowed to take an
unrestricted diet for 2 weeks, and then spironolac-
tone (100 mg/day) was given for a week. Samples of
blood and urine were taken before and after the
spironolactone administration.
Administration of indomethacin. Eleven hyper-
tensive patients were given a diet containing 90
mEq/day of sodium. Furosemide (80 mg/day) was
given orally for 3 days, then indomethacin (150
mg/day, orally) was added for an additional 3 days.
Samples of blood and urine were taken before and
at the end of each 3-day period.
In these experiments, the urine and the plasma
were stored at —20° C for the later determination of
kallikrèin, kinin, PGE, PRA, and PAC.
Resutts
Urinary excretion of kallikrein during ad lib sodi-
um diet. The basal level of urine flow, the urinary
excretion of sodium, potassium, kallikrein, and
PGE, PRA, and PAC in 84 healthy subjects eating
an unrestricted diet are shown in Table 1. Among
these parameters, there were significant correla-
tions between the urinary excretion of kallikrein
and the urine flow (r = 0.30), and between urinary
excretion of kallikrein and that of potassium (r =
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No. of subjects 84
Age, years 40.0 1.6
Mean arterial pressure, mm Hg 94 1
Plasma renin activity, ng/ml/hr 1.5 0.2
Plasma aldosterone concentration, ng/di 6.2 0.5
Urinary volume, mI/day 1878 67
Urinary sodium excretion, mEqlday 281 11
Urinary potassium excretion, mEq/day 52 3
Urinary prostaglandin E excretion, ng/day 736 32
Urinary kallikrein excretion, pg/day 34.5 4.0
0.36). There were also significant correlations be-
tween urinary excretion of PGE and that of sodium
(r = 0.39), between PGE and potassium (r = 0.33),
and between PGE and urine flow (r = 0.30). On the
contrary, no significant correlation was found be-
tween urinary excretion of kailikrein and that of
sodium, between kallikrein and PGE, between kalli-
krein and PRA, between urinary excretion of kalli-
krein and PAC, between urinary excretion of PGE
and PRA, and between urinary excretion of PGE
and PAC.
Circadian variation. Eight often subjects showed
a prominent circadian variation in each parameter.
Figure 1 demonstrates the circadian variation of
urine flow, urinary sodium excretion, urinary potas-
sium excretion, urinary PGE excretion, urinary
kallikrein excretion, urinary kinin excretion, PRA,
and PAC in 10 healthy volunteers.
Urine flow fell to a minimum of 46 7 mi/hr
between 3:00 and 6:00 A.M. and then rose to a
maximum of 112 15 mi/hr between 12:00 noon
and 3:00 P.M. This represented a 71% variation for
the 24-hr mean level. Urinary excretion of sodium
fell to minimum of 5.1 0.8 mEq/hr between 3:00
and 6:00 A.M. and rose to a maximum of 15.0 1.5
mEq/hr between 12:00 noon and 3:00 P.M. This was
a 92% variation for the 24-hr mean level. Urinary
excretion of potassium fell to a minimum of 1.0
0.1 mEq/hr between midnight and 3:00 A.M. and
rose to a maximum of 3.1 0.4 mEq/hr between
9:00 A.M. and 12:00 noon. This was a 102% varia-
tion for the 24-hr mean level. Urinary potassium
excretion changed 3 hours earlier than the other
parameters. Urinary excretion of kallikrein rose to
a maximum of 2.57 0.49 pg/hr between 6:00 and
9:00 A.M. and then fell to a minimum of 1.22 0.33
pg/hr between 3:00 and 6:00 P.M. This was an 84%
variation for the 24-hr mean level. Urinary excre-
tion of kinin rose to a maximum of 870 156 ng/hr
between 12:00 noon and 3:00 P.M. and then fell to a
minimum of 418 35 ng/hr between 9:00 P.M. and
Time of day, hr Time of day, hr
Fig. 1. Circadian variation of urinary volume (UV), urinaly
sodium excretion (UNV), urinary potassium excretion (UKV),
urinary prostaglandin E excretion (UPGEV), urinary kaIlikrein
excretion (UKAV), urinary kinin excretion (UKJV), plasma renin
activity (PRA), and plasma aldosterone concentration. Variation
is expressed as a shift from 24-hour mean level of each parame-
ter.
midnight. This was a 64% variation for the 24-hr
mean level. Urinary excretion of PGE fell to mini-
mum of 12.0 1.3 ng/hr between 6:00 and 9:00 A.M.
and then rose to a maximum of 30.0 3 ng/hr
between 12:00 noon and 3:00 P.M. This was an 83%
variation for the 24-hr mean level. A reversed
relation of circadian variation was found between
urinary kinin and urinary kallikrein. Urinary kinin
excretion followed that of kallikrein, with a delay of
6 hours. On the other hand, PRA and PAC rose to
maximum values of 1.97 0.38 ng/ml/hr and 8.4
1.7 ng/dl at 6:00 P.M. and then fell to minimum
valuesof 1.1 0.1 nglml/hrat 12:OOnoonandof2.9
1.3 ng/dl at 6:00 P.M., with 53% and 122%
variations for the 24-hr mean levels, respectively.
Average urinary kinin excretion was significantly
positively correlated with average urine flow (r =
Table 1. Characteristics of normal subjects on an ad Jib sodium
diet
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0.90, P < 0.01), average sodium excretion (r = 0.83,
P < 0.01), and average urinary PGE excretion (r =
0.76, P < 0.05). In contrast with urinary kinin,
average urinary kallikrein excretion was significant-
ly negatively correlated with average urine flow (r
=
—0.83, P < 0.01), average sodium excretion (r =
—0.81, P < 0.01), and average urinary PGE excre-
tion (r =
—0.88, P < 0.01). There was a significant
positive correlation between PAC and urinary kalli-
krein excretion in each case (r = 0.47, P < 0.05).
No significant correlation was found between PRA
and urinary kallikrein excretion or urinary kinin
excretion in each case. For the relation between
urinary PGE and the renin-angiotensin-aldosterone
system, there was a significant positive correlation
between urinary PGE and PAC in each (r = 0.56, P
< 0.01), whereas a significant negative correlation
b
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between PRA and urinary PGE excretion (r =
—0.78, P < 0.01) was noted. There was also a
positive correlation between average urinary PGE
excretion and average urinary sodium excretion (r
= 0.96, P < 0.01), or urine flow (r = 0.93, P < 0.01).
Influence of low sodium diet, high sodium diet,
and high potassium intake. The changes of urine
flow, PRA, PAC, and urinary excretion of sodium,
potassium, kallikrein, PGE, PGF2, and the main
urinary metabolite of PGF2a following the addition
of a diet containing 200 mEq of sodium, 30 mEq of
sodium, 350 mEq of sodium, 350 mEq of sodium
with 96 mEq of potassium chloride are illustrated in
Fig. 2, a and b. During sodium depletion, urinary
excretion of kallikrein and PGF2. tended to in-
crease, and there was a prominent augmentation of
PRA and PAC, whereas urinary PGE excretion
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Fig. 2. Influence of/ow sodium and high sodium diet on urinary volume (UV), urinary sodium excretion (UNV), urinary potassium
excretion (UKV), urinary kallikrein excretion (UKAV), urinary prostaglandin E(UPGEV) and F2, (UPGF, V) excretion, urinary excretion of
main urinary metabolite of PGF2, (PGF2OMUMV), the ratio of urinary PGE excretion to urinary PGF2, excretion to urinary PGF2, main
urinary metabolite excretion (UPGt2,,VIUPGIMUMV). A denotes the first period (7 days), when a diet containing 200 mEqiday of
sodium was given. B denotes the second period (5 days) when a diet containing 30 mEq/day of sodium was given. C is the third period (5
days) when 350 mEq/day of sodium was given. D is the fourth period (3 days) when 350 mEq/day of sodium and 96 mEq/day of potassium
were given. E is the last period (3 days) when 350 mEq/day of sodium with unrestricted potassium diet was given. The numbers in each
period express the days of blood and urine sampling.
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tended to decrease. During high sodium intake,
PRA, PAC, and the urinary PGF2a metabolite were
significantly decreased. The urinary excretion of
kallikrein tended to decrease and the urinary excre-
tion of PGE tended to increase, but these changes
were not significant. Potassium loading induced a
significant increase in PAC, urinary PGE excretion,
and urinary PGF2c, excretion. The urinary excretion
of kallikrein and PGF2a metabolite also tended to
increase after the potassium loading but these
changes were not significant. There were significant
positive correlations between urinary excretion of
kallikrein and that of potassium (r = 0.35, P <
0.05), and between kallikrein and POE (r = 0.54, P
<0.01). No significant correlation was found, how-
ever, between urinary kallikrein excretion and urine
flow, or urinary sodium excretion. On the other
hand, there were significant correlations between
urinary excretion of PGE and urine flow (r = 0.54,
P < 0.01), between PGE and sodium (r = 0.57, P <
0.01), and between PGE and potassium (r = 0.54, P
< 0.01). No significant correlation was found be-
tween urinary kallikrein excretion and PRA, or
PAC. There was also no significant correlation
between urinary POE excretion and PRA or PAC.
Influence of acute water loading. Changes of
urine flow, urinary excretion of potassium, sodium,
kallikrein, kinin, and PGE, PRA, and PAC follow-
ing acute water loading are illustrated in Fig. 3.
Urine flow, urinary kallikrein excretion, urinary
kinin excretion, and urinary POE excretion were
increased rapidly after water loading, reached a
maximum in 45 mm (U4), and remained at this level
for 90 mm. Then the excretion rate fell, returning to
the control level after 165 mm (U8). In contrast to
the urinary kallikrein-kinin and PGE, the PRA and
PAC did not change significantly. The urinary ex-
cretion of potassium and sodium tended to increase
after the water loading but not significantly. There
were significantly positive correlations between uri-
nary kinin excretion and urinary kallikrein excre-
tion. Significantly positive correlations were also
found between the urinary excretion of POE and
that of kinin or kallikrein. Urine flow was highly
correlated with these three parameters, urinary
kinin, urinary kallikrein, and urinary POE.
Influence of acute saline infusion. The changes of
urine flow, the fractional excretion of sodium and
potassium, the urinary excretion of POE, kinin, and
kallikrein, and the PRA and PAC before and after
saline loading are illustrated in Fig. 4. A significant
increase in urine flow, fractional excretion of sodi-
um and urinary excretion of POE, kallikrein, and
kinin were found after the acute saline infusion
despite a decrement of PRA and PAC. There were
significantly positive correlations between urinary
excretion of kinin and kallikrein, between kinin and
PGE, and between kallikrein and PGE. The urine
flow and the fractional excretion of sodium were
highly correlated with the urinary excretion of
kinin, kallikrein, and PGE. In contrast, a negative
correlation was found between PAC and urinary
kinin, or kallikrein, and between PRA and urinary
kinin, or kallikrein.
Effect of furosemide and upright posture.
Changes of urine flow, urinary excretion of kinin,
kallikrein, POE, PGF2a, and PGF2a metabolite, and
PRA and PAC following the i.v. administration of
furosemide and assumption of upright posture are
shown in Table 2. Urine flow and urinary excretion
of sodium, potassium, kinin, kallikrein, POE, and
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Fig. 3. Influence of acute water loading on urinary volume (UV),
urinary sodium excretion (UNV), urinary potassium excretion
(UKV), urinary prostaglandin excretion (UPGEV), urinary kalli-
krein excretion (UKAV), urinary kinin excretion (UK,V), plasma
renin activity (PRA), and plasma aldosterone concentration
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text.
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Table 2. Effects of furosemide and upright posture on each parameter in 16 normal subjectsa
Control
Furosemide
After 30 mm After 120 mm
UV, mI/mm 1.0 0.1 14.6 1.l' 6.6 06d
UNaV, mEq/min 169 16 1928 l35' 812
UKV, mEqimin
PRA, ng/ml/hr
39 5
1.9 0.5
136 10d
5.8 0.8"
90
8.6 07"
PAC,ng/dl 4.3 0.5 8.2 l.l' 15.9 24"
ng/min 0.49 0.07 1.30 018b 0.52 0.05
U0V, ng/min
U1CJF MUMV, ng/min
UKA, ng/min
0.32 0.02
17.1 2.9
44.9 6.7
0.96 0.21"
10.7 1.3"
143.0 21.4C
0.50 0.07
8.2 o9C
70.4 15.3
UK,V, ng/min 10.5 1.9 40.6 8.6' 23.0 54b
a Values are the means SEM. Abbreviations used are UV, urinary volume; UV, urinary sodium excretion; UKV, urinary
potassium excretion; PRA, plasma renin activity; PAC, plasma aldosterone concentration; UPGEV, urinary prostaglandin E excretion;
UF2V, urinary prostaglandin F2 excretion, UPGF2rMUMV urinary excretion of the main urinary metabolite of prostaglandin F2;
UKAV, urinary kallikrein excretion; UKIV, urinary kinin excretion.b p < 0.05.
cp < 0.01.
"P <0.001.
1:H
:P<0.05
:P<0.01
PGF2a were prominently increased within the first 30
mm after the furosemide injection and then returned
to the control level at 120 mm. In contrast to urinary
PGE and PGF2a, the metabolite of urinary PGF2c
was continuously decreased after furosemide ad-
ministration. On the other hand4 PRA and PAC
were continuously increased for 2 hours after the
injection. The time courses of the increase in PRA
and PAC were different from those of urinary kinin,
urinary kallikrein, and urinary PGE, urine flow, and
urinary potassium and sodium concentrations. In
comparison with the early increase in urinary kinin,
kallikrein and PGE, the increases in PRA and PAC
were delayed. There were significantly positive
correlations between the urinary excretion of kinin
and that of kallikrein, between kinin and PGE, and
between kallikrein and PGE. Highly significant
correlations were also found between the urinary
excretion of sodium and that of kinin or kallikrein.
In contrast, no significant correlation was found
between PRA and the urinary excretion of kinin, or
that of kallikrein, and between PAC and the urinary
excretion of kinin or that of kallikrein.
Effect of spironolactone. The changes in the
urinary excretion of sodium, kallikrein, and PGE
following spironolactone administration in 3 pa-
tients with essential hypertension are shown in
Table 3. Urinary kallikrein excretion gradually de-
creased during spironolactone administration, but
the urinary excretion of sodium and PGE increased
immediately after spironolactone administration be-
gan and then decreased gradually to the control
level.
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Fig. 4. Influence of acute saline infusion on urinary volume
(UV), fractional sodium excretion (FENC), fractional potassium
excretion (FEK), urinary prostaglandin E excretion (UPGEV),
urinary kallikrein excretion (UKAV), urinary kinin excretion
(UK,V), plasma renin activity (PRA), and plasma aldosterone
concentration (PAC). Abbreviations are C, control period; S.
after saline infusion.
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Table 3. Effects of spironolactone on each parameter in 3 patients with essental hypertension
Case 1 Case 2 Case 3
UNaV UpGEV UKAV UNAV UPGE UKAV IJNaV UPGEV UKAV
mEqiday ng/day rig/day mEqiday ng/day gIday mEqiday ng/day .gIday
Control period 271 265 57 301 182 8.3 149 151 44
After spironolactone administration
Day 1 497 670 37 357 293 9.0 207 402 40
Day 2 to 3 349 251 42 214 130 2.7 207 265 30
Day4to5 235 187 19 157 255 2.9 147 114 30
Day 6 to 7 283 128 20 217 290 5.0 66 189 20
a Values are presented as an actual value or the mean value in each period. Abbreviations are defined in Table 2.
Table 4. Effects of low sodium diet with an oral administration of furosemide and the additional effect of indomethacin on each
parameter in 11 patients with essential hypertension'
Control Low Na diet + furosemide Low Na diet + furosemide + indomethacin
UNaV, mEqi day 183 22 84 8' 64 7
PRA, ng/ml/hr 1.2 0.2 5.5 1,7L, 1.6 0.2
PAC, ngldl 5.9 1.2 19.1 3.9' 4.8 1.2
UpGEV, nglday 298 62 330 59 170 33b
UKAV, p.g/day 22.4 8.6 37.1 16.7 24.5 8.6
a Abbreviations are defined in Table 2.
b <0.05.
P < 0.01.d P < 0.001.
Effect of indomethacin. The changes in the uri-
nary excretion of sodium, kallikrein, and PGE, and
in PRA and PAC before and after the administration
of indomethacin to hypertensive patients are shown
in Table 4. On a low sodium diet and after the oral
administration of furosemide, PRA and PAC were
prominently increased. Urinary kallikrein excretion
tended to increase but not significantly. Urinary
PGE excretion did not change. On the other hand,
indomethacin induced a significant decrease in
PRA, PAC, and urinary PGE excretion. Urinary
excretion of sodium and kallikrein tended to de-
crease after indomethacin administration but not
significantly.
Discussion
The urinary kallikrein excretion was decreased
after spironolactone administration in patients with
hypertension, and the urinary kallikrein excretion
was increased after stimulation of the renin-angio-
tensin-aldosterone system by furosemide injection
accompanied by upright posture in healthy volun-
teers. But, there was no significant correlation
between urinary kallikrein excretion and PAC after
the furosemide administration, the time courses of
changes in the two variables being quite different.
In the present data, there was also no significant
correlation between the urinary kallikrein excretion
and the PAC before and after the administration of a
low sodium diet, high sodium diet, and potassium
chloride loading in hypertensive patients, although
the urinary kallikrein tended to increase after the
dietary sodium depletion and the potassium chlo-
ride loading, and tended to decrease after the di-
etary sodium repletion. The basal levels of urinary
kallikrein excretion in 84 healthy subjects did not
show any significant correlation with PAC levels.
These data indicate that there may be at ..ther
regulator of the release and/or the generation of
renal kallikrein in addition to aldosterone.
It is well known that there is circadian rhythm in
the secretion of aldosterone [36, 37]. In 1977, Bow-
den et al [38] reported that there was a circadian
rhythm in the excretion of urinary PGE. Little is
known, however, about the circadian variation for
the urinary kallikrein excretion. The present study
clearly indicates the presence of a circadian varia-
tion in the excretion of urinary kinin and kallikrein,
urine flow, urinary sodium excretion, urinary potas-
sium excretion and urinary PGE excretion. How
does the circadian variation of the urinary excretion
of kinin and kallikrein occur? In the present data,
the pattern of urinary kinin excretion coincided
with those of urine flow, urinary sodium excretion,
and urinary PGE excretion. There was also a signif-
icant correlation between urinary kinin excretion
and urine flow, urinary sodium excretion, and un-
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nary PGE excretion. These data indicate that the
urinary excretion of kinin and PGE may depend on
the rate of urine flow or urinary sodium excretion.
In contrast to the urinary kinin excretion, signifi-
cant negative correlations were found between the
urinary kallikrein excretion and the urine flow,
urinary sodium excretion, or urinary PGE excre-
tion. The acrophase of urinary kallikrein excretion
was 6 hours earlier than those of urine flow and
urinary excretion of sodium, kinin, and PGE. These
results indicate that the excretion of urinary kalli-
krein may be independent of urine flow and urinary
sodium excretion.
A highly positive correlation was found in the
circadian variations between urinary kallikrein and
PAC, whereas negative correlations were found
between PAC and urinary kinin excretion, or uri-
nary PGE excretion. The acrophase of urinary
kallikrein excretion was 1.5 hours later than that of
PAC. These data suggest that the circadian varia-
tion of urinary kallikrein may be regulated by
aldosterone. The nadir of urinary kallikrein excre-
tion, however, was found between 3:00 and 6:00
P.M., and then kallikrein excretion increased gradu-
ally despite continuation of the low level of PAC
until midnight. From these results, the regulatory
mechanism of renal kallikrein between 3:00 P.M.
and midnight could not be explained by aldoster-
one. In the present data, a mirror image was found
between the circadian variation in urinary kinin and
kallikrein, with a highly negative correlation being
found between the two. These findings are in good
accordance with the report of Vinci et al [39] that
urinary kinin excretion was low in patients with
Bartter's syndrome in the presence of an augment-
ed urinary kallikrein excretion. How can the dis-
crepancy in the urinary excretion of kallikrein and
kinin be explained? The present data that the phase
of the circadian variation of urinary kinin was
delayed from that of urinary kallikrein and that the
acrophase of urinary kallikrein coincided with the
nadir of urinary kinin and the nadir of the former
with the acrophase of the latter suggest that there
may be a feedback mechanism in the renal kalli-
krein-kinin system by which kallikrein enhances the
kinin generation and then, in turn, accumulated
kinin inhibits the release or the generation of kalli-
krein. This feedback mechanism may contribute to
the regulation of kallikrein, in addition to the regula-
tory effect of aldosterone. The present data that the
circadian rhythm of urinary PGE excretion was
synchronized with that of urinary kinin excretion
suggest that renal kinin may contribute to the
regulatory mechanism of circadian variation of uri-
nary PGE. The synchronization of the circadian
variations of kinin, PGE, urine flow, and urinary
sodium indicates that renal kinin and PGE may be
involved in the regulation of water and sodium
excretion.
In this study, urinary excretion of kinin, kalli-
krein, and PGE was significantly increased after the
acute expansion of the extracelilar fluid volume
with isotonic saline despite inhibition of the renin-
angiotensin-aldosterone system. Similar changes in
urinary excretion of kinin, kallikrein, and PGE were
also found after water loading. These results indi-
cate that acute volume expansion stimulates the
release and/or the generation of renal kallikrein-
kinin and PGE independently of the renin-angioten-
sin-aldosterone system. But, it is very difficult to
ascertain whether the augmented urinary kallikrein-
kinin and PGE are the cause of diuresis and natri-
uresis after acute volume expansion or merely
whether they reflect a washout phenomenon in-
duced by the enhanced urine flow.
There are many reports 1140—42] that the PG
synthetase inhibitor indomethacin inhibits the di-
uresis and the enhancement of PRA and PAC
induced by furosemide. The recent papers by We-
her, Schere, and Larsson [43] and Gerber and Nies
[44] showed that furosemide stimulates the release
of free arachidonic acid, a main precursor of PG's,
in man and in dog. In the present data, however, the
urinary excretion of the PGF2a metabolite was
decreased after the i.v. administration of furose-
mide despite enhancement of urinary excretion of
PGE and PGF2. These data suggest that the aug-
mentation of urinary PGE and PGF2, excretion
following furosemide administration might be due
to the inhibition of PG metabolism, probably by the
inhibition of 1 5-hydroxy prostaglandin dehydrogen-
ase by this diuretic itself, as shown by Paulsrud and
Miller [451, though furosemide also facilitates the
generation of PG's. The present data that the time
course of PRA alteration following furosemide ad-
ministration was different from that of urinary PGE
excretion indicate that the augmentation of urinary
PGE excretion was independent of the renin-angio-
tensin system enhancement by furosemide. Our
data that urinary excretion of kallikrein and kinin
following furosemide administration was highly cor-
related with urinary PGE excretion support the
presence of a linkage between the renal PGE sys-
tem and the renal kallikrein-kinin system. This
linkage was also found after acute volume expan-
sion with saline or water.
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The increased PRA induced by a low sodium diet
and by furosemide administration was found to be
suppressed by the addition of indomethacin. Uri-
nary PGE excretion was not increased, however,
after sodium deprivation despite the increase in
PRA. These data indicate that renal PG. not PGE in
the renal tubular compartment but probably PGI2 in
the vascular compartment, may contribute to the
macula densa mechanism of renin release in man.
Conclusion. The present study demonstrates that
there was a circadian variation in the excretion of
urinary kinin, kallikrein, and PGE, and that the
circadian variation of urinary kallikrein may be
regulated by aldosterone, whereas those of urinary
kinin and PGE may depend on the rate of urine flow
or urinary sodium excretion. The reversed relation
of circadian variation between urinary kinin and
urinary kallikrein suggests that there may be a
feedback mechanism in the renal kallikrein-kinin
system. The urinary excretion of kinin, kallikrein,
and PGE was significantly increased after acute
volume expansion with isotonic saline and water
loading suggesting that the urinary excretion of
PGE, kallikrein, and kinin after acute volume ex-
pansion may be dependent on the rate of urine flow.
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